Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|February 7, 2014
Prognostic significance of miRNA-1 (miR-1) expression in patients with chordomaZhenfeng Duan, Jacson Shen, Xiaoqian Yang, et al.International Journal of Particle Therapy|November 28, 2019
High-Dose Proton Beam-Based Radiation Therapy in the Management of Extracranial ChondrosarcomasAashish D Bhatt, Alex Jacobson, Richard Y Lee, et al.The Oncologist|December 20, 2002
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumorsDavid P Ryan, Thomas Puchalski, Jeffrey G Supko, et al.Plos One|April 4, 2014
Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcomaShang Guo, Hector Lopez-Marquez, Kenneth C Fan, et al.Cancer|November 14, 2013
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptorsSuzanne George, Yang Feng, Judith Manola, et al.Cancer Immunology Research|May 29, 2014
Programmed cell death ligand 1 expression in osteosarcomaJacson K Shen, Gregory M Cote, Edwin Choy, et al.Cancer Chemotherapy and Pharmacology|October 3, 2002
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicityThomas A Puchalski, David P Ryan, Rocio Garcia-Carbonero, et al.Anticancer Research|June 17, 2009
Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordomaJoseph Schwab, Cristina Antonescu, Patrick Boland, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applicationsSteven P Treon, Linda M Pilarski, Andrew R Belch, et al.Cancer|August 12, 2003
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaCaroline Laverdiere, E Anders Kolb, Jeffrey G Supko, et al.Pageof 5